Jeanne Freddura

Corporate Officer/Principal presso COMMUNITY REDEVELOPMENT INC.

Consumer Services

Finance

Health Technology

Profilo

Jeanne Freddura is currently the Senior Vice President-Finance & Development at Community Redevelopment, Inc. Her former job was as a Controller at Syntimmune, Inc. She has a graduate degree from Harvard University and an undergraduate degree from Cambridge College.

Posizioni attive di Jeanne Freddura

Società	Posizione	Inizio
COMMUNITY REDEVELOPMENT INC.	Corporate Officer/Principal	02/02/2022

Tutte le posizioni attive di Jeanne Freddura

Precedenti posizioni note di Jeanne Freddura

Società	Posizione	Fine
Syntimmune, Inc. Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.	Comptroller/Controller/Auditor	-

Vedi nel dettaglio l'esperienza di Jeanne Freddura

Formazione di Jeanne Freddura

Cambridge College	Undergraduate Degree
Harvard University	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Jeanne Freddura

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
COMMUNITY REDEVELOPMENT INC.	Finance

Aziende private	1
Syntimmune, Inc. Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.	Health Technology